Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.

Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs

In this article NVO Follow your favorite stocksCREATE FREE ACCOUNT Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year. Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and the target group, I think around 15 million people…